ArticleGlobal & regional health technology assessment

Cost-effectiveness analysis of abemaciclib with endocrine therapy (ET) versus ET alone for HR+, HER2-, node-positive, high-risk early breast cancer in Italy.

Alison Davie et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.